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Microarray datasetTrends in genetics are transforming in order to identify differential coexpressions of correlated gene expression
rather than the signiﬁcant individual gene. Moreover, it is known that a combined biomarker pattern improves
the discrimination of a speciﬁc cancer. The identiﬁcation of the combined biomarker is also necessary for the
early detection of invasive oral squamous cell carcinoma (OSCC). To identify the combined biomarker that
could improve the discrimination of OSCC, we explored an appropriate number of genes in a combined gene
set in order to attain the highest level of accuracy. After detecting a signiﬁcant gene set, including the
pre-deﬁned number of genes, a combined expression was identiﬁed using the weights of genes in a gene
set. We used the Principal Component Analysis (PCA) for the weight calculation. In this process, we used
three public microarray datasets. One dataset was used for identifying the combined biomarker, and the
other two datasets were used for validation. The discrimination accuracy was measured by the out-of-bag
(OOB) error. There was no relation between the signiﬁcance and the discrimination accuracy in each individual
gene. The identiﬁed gene set included both signiﬁcant and insigniﬁcant genes. One of the most signiﬁcant gene
sets in the classiﬁcation of normal and OSCC includedMMP1, SOCS3 and ACOX1. Furthermore, in the case of oral
dysplasia and OSCC discrimination, two combined biomarkers were identiﬁed. The combined expression
revealed good performance in the validation datasets. The combined genomic expression achieved better perfor-
mance in the discrimination of different conditions than a single signiﬁcant gene. Therefore, it could be expected
that accurate diagnosis for cancer could be possible with a combined biomarker.
© 2013 Published by Elsevier Inc.1. Introduction
It is known that about 20% of oral dysplasia undergoes malignant
transformation to OSCC [1–3] and the local recurrence rate in OSCC
patients, with histologic positive tumor margins, is as high as 70% to
80%. It has been reported that the probability of the recurrence is 30%
to 40% even in patients with negative margins [4]. This indicated that
the histologic examination alone is inadequate in predicting the pro-
gression to cancer and its recurrence [3–5]. Therefore, it is necessary
to identify better ways to predict which patients with oral dysplasia
will develop OSCC and which patients treated for OSCC will develop
recurrence, such that high risk patients can be more rigorously treated.
Gene expression proﬁling has been widely used for cancer research.
Studies with gene expressions are typically performed by comparing
the gene expression levels between diseased and healthy tissues. They
are normally conducted by testing the statistical signiﬁcant changes inMaxillofacial Surgery and Oral
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vier Inc.themean level of expression of each individual gene [6–8].With various
statistical techniques, gene expression patterns have been explored in
many types of cancer. Additionally, most microarray analyses on cancer
have focused on the comparison of tumor and normal tissues; more-
over, genes have been treated individually and the interaction among
them has not been much considered [9]. Therefore, much of the infor-
mation contained in gene expression datasets could be ignored by deal-
ing with genes individually, although the differential expression
approaches have been very successful.
Biologically known genes are often not differently expressed in dis-
eases because themutations in the coding region can affect the function
of the gene without affecting its expression level [8]. This indicates that
a statistically insigniﬁcant gene, which is not differently expressed
between two different phenotypic groups, can be biologically meaning-
ful and thus, it is not reliable to detect a biomarker by signiﬁcance of an
individual gene. Further, genetic trends have been changing fromdiffer-
ential expression to differential coexpression, and from differential
coexpression to differential networking [8,10]. Hence, a set-wise differ-
ential coexpressed analysis can be useful for understanding the biolog-
ical process [11].
Previous studies have reported that a combined biomarker pat-
tern improved the discrimination of disease as well as the sensitivity
318 K.-Y. Kim et al. / Genomics 103 (2014) 317–322and speciﬁcity for cancer diagnosis compared with a single gene
[12,13]. However, these studies considered only the genes which
were known to be related with a disease, when combined. However,
Chen et al. (2008) identiﬁed discriminative gene sets using the sta-
tistical method and showed that the combined gene set achieved
high accuracy in predicting the different phenotypes [3]. They also
considered only the signiﬁcant individual genes for identifying a
combined gene set. However, the individually insigniﬁcant genes
may be inﬂuential as a member of a gene set. Hence, the insigniﬁcant
genes should be considered in the identiﬁcation of a signiﬁcant gene
set, since the combined gene set including these insigniﬁcant genes
could be more discriminative and more biologically meaningful
compared to a gene set with only individually signiﬁcant genes.
Therefore, it is important to identify a coexpressed gene set in addi-
tion to the common differential mean expression testing. In this study,
we investigated the discriminative gene sets betweenOSCC and normal,
OSCC and oral dysplasia, and also identiﬁed the combined gene expres-
sions from the selected gene sets. The combined gene expressions were
evaluated in publicly available two microarray datasets.2. Results
2.1. The association of the signiﬁcance and prediction accuracy in a
single gene
We explored the association of the signiﬁcance and the prediction
accuracy of an individual gene (Figs. 1A and B). We used OOB errorFig. 1. The association of signiﬁcance and OOB error rates of individual genes in (A) whole gene
there is an association of signiﬁcance and prediction accuracy. (C) The association of signiﬁcan
10,000 times repeatedly; therefore, each plot showed 10,000 points. The vertical axis, OOB errrate as a measure of prediction accuracy. Here, we calculated the signif-
icance and OOB error rates in classifying normal and OSCC patients.
Figs. 1A and B showed that there was no association of signiﬁcance
or a prediction accuracy of a single gene. It indicated that all of the sig-
niﬁcant genes are not discriminative. Therefore, it is necessary to iden-
tify a gene set, including signiﬁcant and insigniﬁcant genes, in order to
maximize the prediction accuracy.
2.2. The association of the signiﬁcance and prediction accuracy in a gene set
In order to explore the association of signiﬁcance andOOB error rates
of genes in a gene set, we selected gene sets with 3 genes 10,000 times
repeatedly and plotted out their relation of genes in a gene set (Fig. 1C).
Fig. 1C illustrated that insigniﬁcant genes can achieve high prediction
accuracy and lowOOB error rates (gray rectangle in Fig. 1C). Therefore, it
indicated that the combination of genes, including such insigniﬁcant
genes, can be more appropriate as a biomarker; a combined biomarker.
2.3. Appropriate number of genes to be combined for a biomarker
To identify a combined expression of genes, it is necessary to decide
howmany genes should be combined.We simulated gene sets with size
1 to 5, 10,000 times repeatedly, and explored the association of the OOB
error rates and the number of genes (Fig. 2).
When gene set sizewas 1, the OOB error rates were same to those in
Fig. 1A. The OOB error rates were decreased as the size of the gene set
was increased (Fig. 2). We decided to use 3 as the gene set size, sinces, (B) randomly selected 1000 genes. The points are gathered around the gray rectangle if
ce and OOB error rates of 3 genes in a gene set. The gene sets with 3 genes were selected
or rate, was used as a measure of predictability.
Fig. 2. The association of the number of genes in a gene set and the OOB error rates of the
gene set. Gene set size was 1 to 5; we randomly selected genes with the same size 10,000
times, repeatedly, in order tominimize the selection bias. In boxplot, the bottomand topof
the box are the ﬁrst and third quartiles, and the band inside the box is the second quartile
(median). The ends of the dotted lines represent inner fences, and any data not included
between the dotted lines are plotted as an outlier with a dot.
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distribution of OOB error rates.
2.4. Seed gene selection by signiﬁcance and OOB error rate
In order to decide the seed gene, we selected the most signiﬁcant
gene and the highest predictive gene. Twenty genes selected byTable 1
Summary of identiﬁed gene sets and the validation of them using GSE30784.
Classiﬁcation group Gene name Weights by PCA
Normal & OSCC MMP1, SOCS3, ACOX1 0.916, 0.839,−
MMP1, RUNX2, MTERFD2 −0.907,−0.81
FAP, MTAP, LAMB1 0.951, 0.309, 0.9
FAP, MTAP, LAMB1 −0.947,−0.30
FAP, MTAP, RYK 0.810, 0.441, 0.7
FAP, MTAP, ESD −0.759,−0.77
FAP, MTAP, FCER1A −0.855,−0.40
FAP, MTAP, C10orf128 0.816, 0.426,−
FAP, MTAP, MARVELD3 0.727, 0.736,−
Dysplasia & OSCC PTPRJ, NEK6, SLC44A1 −0.732,−0.74
EVA1A, NEK6, KLHL8 0.867, 0.889, 0.2
Table 2
Comparison of the performance of the identiﬁed gene sets with that of the previous study [3,2
Data Gene sets identiﬁed in previous study [3] Weights from
GSE30784 LAMC2, COL4A1 7.8739, 7.6269
COL1A1, PADI1 2.4377,−2.88
GSE9844 LAMC2, COL4A1 7.8739, 7.6269
COL1A1, PADI1 2.4377,−2.88
Data Gene sets identiﬁed in our study Weights by PC
GSE30784 MMP1, SOCS3, ACOX1 0.916, 0.839,−
MMP1, RUNX2, MTERFD2 −0.907,−0.8
FAP, MTAP, C10orf128 0.816, 0.426,−
GSE9844 MMP1, SOCS3, ACOX1 0.916, 0.839,−
MMP1, RUNX2, MTERFD2 −0.907,−0.8
FAP, MTAP, C10orf128 0.816, 0.426,−predictability and signiﬁcance were summarized in Supplementary
Tables 1 and 2.
The selected genes by the OOB error rate were identiﬁed by their in-
dividual predictability. Moreover, the selected genes by signiﬁcance
were identiﬁed by independent two samples t-test. We used whole
probes in this stage, which are the not corrected duplicated gene IDs.
MMP1 and FAP were the most predictable and the most signiﬁcant
genes in classifying normal and OSCC groups (Supplementary Table 1).
PTPRJ and EVA1A were the most predictable and the most signiﬁcant
genes in classifying oral dysplasia and OSCC groups (Supplementary
Table 2). We identiﬁed the combined biomarkers with these two seed
genes.2.5. Identiﬁed gene sets and the validation of the combined expressions
The signiﬁcant gene sets were identiﬁed with seed genes, and the
weights of each genewere calculated by PCA. The sensitivity, speciﬁcity
and accuracy of each gene set were summarized in Table 1.
After identifying a signiﬁcant gene set with three genes, the com-
bined expression was calculated using weights of genes from PCA. The
gene setwithMMP1, RUNX2 andMTERFD2had themost discriminative
power to separate OSCC from normal (accuracy = 0.981). Further, the
gene set with EVA1A, NEK6 and KLHL8 had the most discriminative
power to separate oral dysplasia from OSCC (accuracy = 0.924). In the
case of classiﬁcation of OSCC and oral dysplasia, oral dysplasia groups
tended to allocate to OSCC. Therefore, the speciﬁcity was low despite the
high accuracy.
We compared the performance of the identiﬁed gene sets with that
of the previous study (Table 2).
We compared the performance of two combined expressions identi-
ﬁed by Chen et al. [3], with our three combined expressions, in two
datasets, GSE30784 and GSE9844. In both datasets, the three combined
expressions, which were identiﬁed in our study, demonstrated better
performance compared to the previous study, particularly in GSE9844.Sensitivity Speciﬁcity Accuracy
0.859 0.982 0.933 0.972
1, 0.811 0.988 0.956 0.981
41 0.976 0.911 0.962
6,−0.935 0.970 0.889 0.953
03 0.964 0.867 0.953
1,−0.028 0.946 0.8 0.915
4, 0.830 0.982 0.933 0.972
0.700 0.982 0.933 0.971
0.354 0.940 0.778 0.906
6, 0.553 0.952 0.529 0.913
93 0.985 0.588 0.924
9].
logistic regression Sensitivity Speciﬁcity Accuracy
0.976 0.911 0.962
41 0.976 0.911 0.962
0.923 0.833 0.895
41 0.846 0.667 0.789
A Sensitivity Speciﬁcity Accuracy
0.859 0.982 0.933 0.972
11, 0.811 0.988 0.956 0.981
0.700 0.982 0.933 0.971
0.859 0.9612 0.917 0.947
11, 0.811 0.9612 0.917 0.947
0.700 0.9612 0.917 0.947
Fig. 3. Comparison of the combined expression in normal and cancer groups. Gene lists in a gene setwere (A)MMP1, SOCS3 and ACOX1; (B)MMP1, RUNX2 andMTERFD2' (C) FAP, MTAP
and C10orf128. CN, CC, HNN andHCC represented cervical normal, cervical cancer, head & neck normal and head & neck cancer, respectively. In boxplot, the bottom and top of the box are
theﬁrst and third quartiles, and the band inside the box is the second quartile (median). The ends of the dotted lines represent inner fences, and any data not included between the dotted
lines are plotted as an outlier with a dot.
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(Fig. 3).
The combined expressions were clearly differentiated between nor-
mal and cancer groups. The combined expressions of MMP1, SOCS3,
ACOX1 and FAP, MTAP and C10orf128 were up-regulated in cancer.
Moreover, the combined expressions of MMP1, RUNX2 and MTERFD2
were down-regulated in cancer compared to the normal group. The
combined expressions in cancer patient groups were distributed more
extensively compared to those in the normal group.
We explored the two combined expressions in classifying oral dys-
plasia and cancer in GSE30784 (Fig. 4).
The signiﬁcance and predictability in individual gene were not
related in oral dysplasia and cancer classiﬁcation. Further, predictability
ofmost geneswas about 50%, evenwhen their signiﬁcanceswere strong
(data not shown). However, the predictability was increased as two
more genes were combined (Fig. 4).
The OOB error rates, which were shown in Fig. 4, were the mean
values of OOB error rates calculated from 100 times oral dysplasia and
cancer classiﬁcation. The reason for the 100 repetitions is that the size
of these two groups was very unbalanced; we randomly sampled 17
cancer cases 100 times for amore accurate comparison. Fig. 4 illustrated
that the combined expressions were more predictive compared to
single genes. It indicated that the combined expressions could be
more appropriate as a biomarker.Fig. 4. Predictability comparison of combined expression and individual gene expression3. Conclusion and discussion
There can be two approaches to the analysis of gene expression data
collected in microarray studies. The ﬁrst identiﬁes genes that show sig-
niﬁcantly different expressions between conditions. The second is to
identify the patterns of coexpressed gene expressions [11,15]. Identify-
ing an individually signiﬁcant gene expressionmight even lead to incor-
rect conclusions about the involvement of particular pathways in
disease conditions [8,16]. By the way, different coexpression provides
information that would be missed using the classical methods, which
focus on the identiﬁcation of differently expressed genes, and may be
engendered by different biological mechanisms [15]. Therefore, it is
vital to perform differential coexpression analyses in addition to the
common differential mean expression test.
Previous studies have reported various methods for the identiﬁca-
tion of coexpressed genes and gene network [6,8,10,11,15]; further,
some studies reported that the combined biomarkers improved the
predictability of speciﬁc cancers [3,12,13].
In this study, we detected coexpressed genes and identiﬁed the
combined biomarker of these coexpressed genes using PCA. Nine
coexpressed gene sets were identiﬁed, which were highly effective in
the classiﬁcation of normal and OSCC, and 2 gene sets for the classiﬁca-
tion of oral dysplasia and cancer. Two of the most signiﬁcant gene sets
in the classiﬁcation of normal and OSCC included MMP1, SOCS3,. Two combined expressions were identiﬁed for dysplasia and cancer classiﬁcation.
Table 3
Summary of the datasets used in this work.
GSE30784 [3] GSE9844 [29] GSE6791 [14]
N = 229 N = 38 N = 75
Age 19–39 24 Mean 56.40 (stda 12.22) Mean 54.41
40–49 42 Median 57 Range 18–88
50–59 67 Range 37–82
60–68 96
Gender F 67 F 9 F 48
M 162 M 29 M 34
NA 3
Cancer 167 OSCC 26 Cervical cancer (CC) 20
Normal 45 Normal 12 Cervical normal (CN) 8
Dysplasia 17 HN cancer (HNC) 42
HN normal (HNN) 5
N stage Negative 15
Positive 11
Platform GPL570
[HG-133_Plus_2]
Affymetrix Human
Genome U133
Plus 2.0 Array
GPL570
[HG-133_Plus_2]
Affymetrix Human
Genome U133
Plus 2.0 Array
GPL570
[HG-133_Plus_2]
Affymetrix Human
Genome U133
Plus 2.0 Array
54,675 probes 54,675 probes 54,675 probes
a std: standard deviation.
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(accuracy = 0.981).
Matrix metalloproteinases 1 (MMP1) was reported as a biomarker
related with cancers [17,18], particularly with oral cancer [19–21].
SOCS3 was reported to be related with cancer cell growth [22] and an
endogenous inhibitor of pathologic angiogenesis [23]. ACOX1 has not
been much studied; however, it can play a role as a member of a gene
set. The decreased expression of RUNX2 was observed on colorectal
cancer [24]. And it was reported that the increased expression of
RUNX2 modulated the expression of apoptosis-associated factors,
speciﬁcally Bcl-2 [25].
In the case of oral dysplasia and OSCC discrimination, two combined
biomarkers were identiﬁed. The gene set with EVA1A, NEK6 and KLHL8
had themost discriminative power to separate oral dysplasia fromOSCC
(accuracy = 0.924). The gene set with PTPRJ, NEK6 and SLC44A1
achieved 91.3% accuracy in the classiﬁcation of oral dysplasia from
OSCC.
It was reported that PTPRJ has been associated with the protective
effects for breast cancer risk; however, there was no signiﬁcant increase
in the risk for colorectal cancer with variants or haplotypes in PTPRJ
[26]. NEK6 is known to play a critical role in mitotic cell cycle progres-
sion [27,28]; the dysregulation of NEK6 expression plays a key role in
oncogenesis [28]. Recent studies have shown that NEK6 is upregulated
in various cancers [27] and NEK6 is involved in the pathogenesis of
hepatocellular carcinoma, and it may be a favorable independent prog-
nostic parameter for hepatocellular carcinoma [28]. Jee et al. (2010)
suggested that the downregulation of NEK6 is required for the onset
of p53-induced cellular senescence and imply a possible role of NEK6
in tumorigenesis [27].
Some genes in a combined gene set were already reported to be
related with cancer progression in previous studies, whereas some
genes were not. However, it is possible that these unreported genes
have been playing a role as amember in a combined gene set. Therefore,
the functional study of a combined gene set including genes, which are
not still known, would be meaningful.
The performance of the three combined expressions identiﬁed in
this study was compared with previous study in two public microarray
datasets, GSE30784 and GSE9844. In both datasets, the three combined
expressions identiﬁed in this study showed better performance com-
pared to those of the previous study, particularly in GSE9844. The limi-
tation of this study is that the identiﬁed biomarkers were evaluated
using independent two different microarray data sets, not biologically
validated. Therefore, the biological validation of the identiﬁed bio-
markers would be our further work in addition to the implementation
of prognosis prediction system including the biomarkers.
For diagnosis of the speciﬁc disease, the signiﬁcant biomarker has
been commonly used. However, the performance of diagnosis can be
improved by the combined biomarker including insigniﬁcant genes,
which are not signiﬁcantly differently expressed between diseased
and normal groups. It is why the insigniﬁcant genes can play an impor-
tant role in a combined biomarker by combiningwith signiﬁcant genes.
And, it could be possible to investigate the still unknown biological
pathways of the identiﬁed combined biomarkers.
In conclusion, the combined expression was more predictive com-
pared to individual signiﬁcant genes, which implies that it could be a
biomarker for more accurate diagnosis of cancer.
4. Materials and method
4.1. Data preparation
We used three publicly available expression datasets in this study.
The ﬁrst dataset was published by Chen et al. (GSE30784) [3], which
was utilized for detecting signiﬁcant gene sets. This dataset consisted
of 45 normal controls, 17 oral dysplasias and 167 oral squamous cell
carcinomas. Two further datasets were used for the validation of thecombined gene expression. These were cDNAmicroarray datasets pub-
lished by Ye et al. (GSE9844) [29] and Pyeon et al. (GSE6791) [14]. The
datasets are summarized in Table 3.
4.2. Statistical method
In order to decide the appropriate number of genes in a gene set, we
compared the out of bag (OOB) error rates of a gene set with a different
size. To calculate OOB error rates, we used Random Forest algorithm
(RF) [30], with the following steps.
(1) Generate n datasets of bootstrap samples {B1, B2,…, Bn} by
allowing repetition of the same sample.
(2) Use each sample Bk to construct a Tree classiﬁer Tk to predict
those samples that are not in Bk, called out-of-bag (OOB) sam-
ples. These predictions are called out-of-bag estimators.
(3) Final prediction is the average of out-of-bag estimators over all
bootstrap samples and we get average of them which is overall
classiﬁcation error (OOB error).
OOB error rates were calculated 10,000 timeswith a resampled gene
set with the same size for minimizing the selection bias. The gene set
with a minimum OOB error was identiﬁed as a signiﬁcantly discrimina-
tive gene set. The process of selecting a signiﬁcant gene setwas summa-
rized in Fig. 5, where the appropriate gene set size is supposed to be 3.
We identiﬁed the combined expression of genes in a gene set using
the Principal Component Analysis (PCA) [31,32]. PCA is a simple non-
parametric statistical method of extracting relevant information from
complex data sets involving multiple variables [31], and can be used
in relatively small data sets. PCA uses an orthogonal transformation in
order to convert correlated variables into uncorrelated variables,
known as principal components. The shortcoming of PCA is that the
methods for ﬁnding the principal components have trouble with high
dimensional data or large numbers of data points. However, we will
apply PCA to the dataset which contains pre-identiﬁed number of
genes and several tens of data points. Principal component is represent-
ed in the form of linear combinations of the original variables, and it is
calculated according to the following formula for each case; we call it
the combined expression of genes, or combined biomarker.
Combined expression = w1g1 + w2g2 + w3g3, where w1, w2, and
w3 are the weights of genes and g1, g2, and g3 are gene expressions.
Fig. 5. Process for signiﬁcant gene set selection. Seed gene can be themost signiﬁcant gene or themost discriminative gene. Also, a gene is added into a gene setwhen the gene set reaches
the highest predictability, until the gene set size is 3.
322 K.-Y. Kim et al. / Genomics 103 (2014) 317–322The effectiveness of the combined expressionwasmeasured by sen-
sitivity, speciﬁcity and accuracy. The statistical analysis was performed
using R (version 2.13.0) [33].
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ygeno.2013.11.007.
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